Skip to main content

Professor Philip Chowienczyk

Professor of Clinical Cardiovascular Pharmacology

Research interests

  • Cardiovascular

Biography

Philip Chowienczyk is a Professor of Clinical Cardiovascular Pharmacology in the School of Cardiovascular Medicine & Sciences. 

    Research

    ageing
    Centre for Ageing Resilience In a Changing Environment - CARICE

    Welcome to the Centre for Ageing Resilience in a Changing Environment: CARICE

    News

    Lower blood pressure reduces cardiovascular disease for children with chronic kidney disease

    The HOT-KID clinical trial looked at how lowering blood pressure in children with chronic kidney disease could prevent cardiac remodelling and associated...

    Kidneys

    Paper by King's researchers makes Readers' Choice List 2021

    The article was selected as one of The Pharmacogenomics Journal’s 15 most cited or shared articles in 2021.

    Blood testing

    Researchers reveal that first-phase ejection fraction is associated with increased mortality in patients with COVID-19

    Researchers reveal that first-phase ejection fraction is associated with increased mortality in patients with COVID-19

    heart ejection fraction story

      Research

      ageing
      Centre for Ageing Resilience In a Changing Environment - CARICE

      Welcome to the Centre for Ageing Resilience in a Changing Environment: CARICE

      News

      Lower blood pressure reduces cardiovascular disease for children with chronic kidney disease

      The HOT-KID clinical trial looked at how lowering blood pressure in children with chronic kidney disease could prevent cardiac remodelling and associated...

      Kidneys

      Paper by King's researchers makes Readers' Choice List 2021

      The article was selected as one of The Pharmacogenomics Journal’s 15 most cited or shared articles in 2021.

      Blood testing

      Researchers reveal that first-phase ejection fraction is associated with increased mortality in patients with COVID-19

      Researchers reveal that first-phase ejection fraction is associated with increased mortality in patients with COVID-19

      heart ejection fraction story